Patients and Methods We retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS‐102 (35 mg/m2, twice a day) with (T‐B group) or without Bmab (TAS‐102 monotherapy; T group) between July 2014 and December 2018. The primary endpoint was median overall ...
We conducted a single-center retrospective cohort study in patients with colorectal cancer who received Bmab+TAS-102. We compared overall survival (OS) between patients who developed grade≥3 neutropenia during the treatment period and those who did not. To account for immortal time bias, we used...